insulin glargine
Drug Name | Form | Strength | Formulary Unrestricted | Formulary Restricted | Non-Formulary | Interchange |
---|---|---|---|---|---|---|
Basaglar KwikPen | SOLUTION, SUBCUTANEOUS | 100 units/mL | ||||
Lantus | SOLUTION, SUBCUTANEOUS | 100 units/mL | ||||
Rezvoglar | SOLUTION, SUBCUTANEOUS | 100 units/mL | ||||
Semglee | SOLUTION, SUBCUTANEOUS | 100 units/mL | ||||
Toujeo SoloStar | SOLUTION, SUBCUTANEOUS | 300 units/mL |
ORDERED FORMULATION
THERAPEUTIC INTERCHANGE
NOTES
insulin glargine (Toujeo SoloStar)
insulin glargine
Interchanged on a 1 unit : 1 unit ratio with same dosing frequency.
insulin glargine (Basaglar Kwikpen)
insulin glargine
Interchanged on a 1 unit : 1 unit ratio with same dosing frequency.
Approved to round DOWN to nearest whole unit if calculations result in dose in fractions.
Standard administration times:
once daily (except qAM) = 2100
once daily in the morning = 0900
twice daily = 0900 and 2100
now = now
Patients with orders for the hospital’s adult sliding scale insulin order set have orders to implement the hospital’s hypoglycemia orders. However, some patients have orders for scheduled or PRN insulin without use of the sliding scale insulin order set. These patients may not have PRN orders for treatment of hypoglycemia.
To improve safety with insulin use, the following policy has been approved by the P&T Committee:
Semglee and Rezvoglar has been classified as therapeutically equivalent to Lantus for adult and pediatric patients. The most cost-effective insulin glargine product will be used in a specific patient, setting, or time period.
Reviewed: 28 July 2015 (Toujeo), and 19 Jan 2017 (Basaglar pediatrics), and 24 Jan 2017 (Basaglar), and February 2021, and June 2022 (Rezvoglar)